{"entity":{"id":"nct06123494","kind":"trial","name":"SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen","aka":[],"tldr":"A phase 3 trial of Trastuzumab rezetecan, Docetaxel and Ramucirumab in gastric & gastro-oesophageal junction cancer, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.","summary":"SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen is a phase 3 interventional study registered as NCT06123494 by Jiangsu HengRui Medicine Co., Ltd., with 360 participants planned, started 2024-01-09 and due to reach its primary completion in 2027-06-30. Interventions recorded: SHR-A1811 and Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06123494","url":"https://clinicaltrials.gov/study/NCT06123494"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["gastric"],"sections":[],"technologies":[],"targets":[],"drugs":["trastuzumab-rezetecan","docetaxel","ramucirumab"],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06123494","phase":"3","setting":"A Phase 3, Multicenter, Randomized, Open-label Study of SHR-A1811 (HER2-ADC) Compared With the Chemotherapy Treatment Chosen by the Investigators for Subjects With HER2-positive Metastatic and/or Unresectable Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Who Have Progressed on or After First-line Anti-HER2 Therapy-containing Regimen","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","enrolled":360,"outcomes":[]},"route":"/trials/nct06123494/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"}],"drug":[{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/"},{"id":"ramucirumab","kind":"drug","name":"Ramucirumab","route":"/drugs/ramucirumab/"},{"id":"trastuzumab-rezetecan","kind":"drug","name":"Trastuzumab rezetecan","route":"/drugs/trastuzumab-rezetecan/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}]}}